Safety of pioglitazone during and after radiation therapy in patients with brain tumors: a phase I clinical trial
ConclusionPioglitazone was well tolerated by brain tumor patients undergoing RT. 45 mg is a safe dose to use in future efficacy trials.
Source: Journal of Cancer Research and Clinical Oncology - Category: Cancer & Oncology Source Type: research
More News: Actos | Brain | Brain Cancers | Brain Tumor | Cancer | Cancer & Oncology | Chemotherapy | Clinical Trials | Diabetes | Endocrinology | Neurology | Radiation Therapy | Toxicology